AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...

AstraZeneca said on Wednesday its asthma drug Fasenra failed to control the rate of flare-ups in patients with chronic obstructive pulmonary disease (COPD) in a late-stage study, in a setback to ...